Delcath Systems (NASDAQ:DCTH) Upgraded by StockNews.com to “Sell”

StockNews.com upgraded shares of Delcath Systems (NASDAQ:DCTH) to a sell rating in a research report released on Wednesday morning.

Separately, HC Wainwright increased their price target on shares of Delcath Systems from $18.00 to $20.00 and gave the company a buy rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus target price of $18.50.

Delcath Systems Trading Down 6.3 %

Shares of Delcath Systems stock opened at $4.77 on Wednesday. The stock has a market capitalization of $117.15 million, a price-to-earnings ratio of -1.61 and a beta of 0.51. Delcath Systems has a 1-year low of $2.25 and a 1-year high of $7.99. The firm’s 50-day moving average price is $4.37 and its two-hundred day moving average price is $3.85.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Tuesday, March 26th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.19. Delcath Systems had a negative net margin of 2,308.86% and a negative return on equity of 563.60%. The business had revenue of $0.54 million for the quarter, compared to analysts’ expectations of $0.48 million. During the same period in the prior year, the firm earned ($0.86) earnings per share. As a group, equities research analysts predict that Delcath Systems will post -1.9 EPS for the current year.

Insider Activity at Delcath Systems

In other Delcath Systems news, Director Gil Aharon acquired 26,882 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The shares were acquired at an average cost of $3.72 per share, for a total transaction of $100,001.04. Following the completion of the acquisition, the director now directly owns 1,069,710 shares of the company’s stock, valued at approximately $3,979,321.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 21.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Delcath Systems

Several large investors have recently bought and sold shares of DCTH. Cibc World Market Inc. lifted its holdings in Delcath Systems by 4.0% in the first quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock valued at $568,000 after buying an additional 3,432 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Delcath Systems in the first quarter worth $75,000. Vanguard Group Inc. raised its holdings in Delcath Systems by 5.7% in the first quarter. Vanguard Group Inc. now owns 360,900 shares of the company’s stock worth $2,309,000 after purchasing an additional 19,605 shares during the period. Millennium Management LLC acquired a new stake in Delcath Systems in the second quarter worth $40,000. Finally, Tower Research Capital LLC TRC raised its holdings in Delcath Systems by 107.8% in the first quarter. Tower Research Capital LLC TRC now owns 4,663 shares of the company’s stock worth $26,000 after purchasing an additional 2,419 shares during the period. 61.12% of the stock is currently owned by institutional investors and hedge funds.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.